Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GR-1 + lactobacillus reuteri RC-14
- Development stage
- Phase 1
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal
01
Overview
Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14 is a specific probiotic combination developed to support and restore the female urogenital microbiome. The two strains were originally isolated from the distal urethra and vagina of healthy women by researchers Gregor Reid and Andrew Bruce at Western University. *L. rhamnosus* GR-1 is known for its ability to colonize the vaginal tract and inhibit the adhesion of uropathogens, while *L. reuteri* RC-14 (formerly classified as *L. fermentum*) produces biosurfactants and hydrogen peroxide that disrupt pathogen biofilms. Together, they work by lowering vaginal pH through lactic acid production and competing with pathogenic bacteria such as *Gardnerella vaginalis*, *Escherichia coli*, and *Candida* species. The combination is widely used as an oral or vaginal intervention for bacterial vaginosis, yeast vaginitis, and the prevention of recurrent urinary tract infections.
- Brand names
- Vagi-GardOptiBac Probiotics For WomenBlackmores Probiotics Women's Flora Balance
- Other names
- Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14Lactobacillus rhamnosus GR-1 + Limosilactobacillus reuteri RC-14
Beyond the preview
Go deeper on lactobacillus rhamnosus GR-1 + lactobacillus reuteri RC-14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GR-1 + lactobacillus reuteri RC-14.